Novartis Earns Near-Best Overall Rating As Profit Growth Climbs

Blockhead
Yesterday

Novartis (NVS) saw its IBD SmartSelect Composite Rating jump to 96 Wednesday, up from 93 the day before. The new score indicates that shares of the company, which is No. 1 in its industry group, are now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria.

X NOW PLAYING Find Top Growth Stocks With The IBD Screen Of The Day

Winning stocks often have a 95 or higher grade in the early stages of a new price run, so that's a good starting point when looking for the best stocks to buy and watch.

Novartis stock is currently forming a cup with handle base, with a 112.98 buy point. Look for the stock to break out in volume at least 40% above average. Wednesday the drugmaker


Discover The 3 Keys To Successful Stock Investing


Novartis A Favorite Of Big Funds

The stock also sports an 89 EPS Rating, which means its recent quarterly and longer-term annual earnings growth is outpacing 89% of all stocks. Its Accumulation/Distribution Rating of A shows heavy buying by institutional investors, such as mutual funds and pension funds, over the last 13 weeks.

The Swiss company posted a 29% increase in earnings for Q4, to $1.29 per share. That marks two straight reports with rising EPS growth. Sales increased 15% year over year to $13.6 billion, up from 9% growth the prior quarter. Novartis is expected to report first quarter results on or around April 29.

IBD Newsletters

Get exclusive IBD analysis and actionable news daily.

IBD Newsletters

Get exclusive IBD analysis and actionable news daily.

Please enter a valid email address
Please select a newsletter

Get these newsletters delivered to your inbox & more info about our products & services. Privacy Policy & Terms of Use

Thank You!

You will now receive IBD Newsletters

Something Went Wrong!

Please contact customer service

Novartis earns the No. 1 rank among its peers in the 33-stock Medical-Ethical Drugs industry group. Phibro Animal Health (PAHC) and Jazz Pharmaceuticals (JAZZ) are also among the group's highest-rated stocks.

This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.

Please follow James DeTar on Twitter @JimDeTar

YOU MAY ALSO LIKE:

Which Companies Are Now Outperforming 95% Of All Stocks?

View The Top-Rated Growth Stocks To Buy And Watch Right Now

See Which Stocks Just Came On — And Off — IBD's Top Stock Lists

Ready To Grow Your Investing Skills? Join An IBD Meetup Group!

Identify Bases And Buy Points With Pattern Recognition From MarketSmith

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10